Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Thyroid nodule Stories

2014-03-11 08:29:14

SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress. The live webcast and subsequent replay may be accessed by visiting Veracyte's website...

2014-03-04 23:30:38

Center for Diagnostic Imaging of Miami announces a new thyroid scanning technology. Miami, FL (PRWEB) March 04, 2014 The best way to treat any disease is to prevent it from occurring in the first place. This is the idea behind preventative medicine, which not only prevents disease, but prevents the costs that come with it. Diseases like hypothyroidism can cause serious health issues such as obesity and a higher risk for heart disease. That is why CDI Miami, a medical imaging center...

2014-03-03 16:25:19

-- Presentation and Webcast Scheduled for Tuesday, March 4, at 8 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34(th) Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolph room at The Boston Marriott Copley Place in Boston, Mass....

2014-02-26 08:28:18

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 34(th) Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m. ET in Boston, Mass. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to...

2014-02-14 23:23:27

Molecular diagnostic testing, which analyzes thyroid nodule FNA biopsy specimens, is rapidly emerging as a useful tool for evaluation of cytologically indeterminate thyroid nodules that otherwise would require diagnostic surgery. Portland, OR (PRWEB) February 14, 2014 Molecular diagnostic testing, which analyzes thyroid nodule FNA biopsy specimens, is rapidly emerging as a useful tool for evaluation of cytologically indeterminate thyroid nodules that otherwise would require diagnostic...

2014-02-05 08:28:49

SOUTH SAN FRANCISCO, Feb. 5, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to...

2013-12-16 16:25:49

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC). The new policy applies to approximately 13 million of Cigna's medical customers and is effective immediately. The Afirma GEC is used to...

2013-11-13 08:29:25

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate and sub-classified as Hurthle cell neoplasms by cytopathology. The findings were presented in a poster session at the American Society of...

2013-11-11 08:28:10

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25, 2013. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The live webcast and subsequent replay may be accessed by visiting Veracyte's...

2013-10-23 16:29:37

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2013 /PRNewswire/ -- Data from a new long-term, multicenter study confirm the accuracy of the Afirma Gene Expression Classifier (GEC) in identifying benign thyroid nodule fine needle aspiration (FNA) biopsies among those initially deemed indeterminate, or inconclusive, by cytopathology, Veracyte, Inc. announced today. The findings further support physicians' decision to avoid diagnostic surgery on such patients and monitor them instead - and...